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Abstract
Cyclooxygenase-2 (COX-2) overexpression and muta-
tions of p53 (a known COX-2 regulator) are inversely as-
sociated with microsatellite instability—high (MSI-H)
and CpG island methylator phenotype (CIMP), charac-
terized by extensive promotermethylation, is associated
with MSI-H. However, no studies have comprehensively
examined interrelations between COX-2, p53, MSI, and
CIMP. Using MethyLight, we measured DNA methyla-
tion in five CIMP-specific gene promoters [CACNA1G,
CDKN2A (p16/INK4A), CRABP1, MLH1, and NEUROG1]
in relatively unbiased samples of 751 colorectal cancer
cases obtained from two large prospective cohorts; 115
(15%) tumors were CIMP-high (>_ 4 of 5 methylated
promoters), 251 (33%) were CIMP-low (1 to 3 methylated
promoters), and the remaining 385 (51%) were CIMP-0
(no methylated promoters). CIMP-high tumors were
much less frequent in COX-2+/p53+ tumors (4.6%) than
in COX-2+/p53 tumors (19%; P < .0001), COX-2/p53+
tumors (17%;P= .04), andCOX-2/p53 tumors (28%;P<
.0001). In addition, COX-2+/p53+ tumors were signifi-
cantly less common in MSI-H CIMP-high tumors (9.7%)
than in non–MSI-H CIMP-low/CIMP-0 tumors (44–47%;
P < .0001). In conclusion, COX-2 andp53alterationswere
synergistically inversely correlated with both MSI-H and
CIMP-high.Our data suggest that a combinedanalysis of
COX-2 and p53 may be more useful for the molecular
classification of colorectal cancer than either COX-2 or
p53 analysis alone.
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Introduction
Transcriptional inactivation by cytosine methylation at pro-
moter CpG islands of tumor-suppressor genes is thought to
be an important mechanism in human carcinogenesis [1]. A
number of tumor-suppressor genes, including CDKN2A
(cyclin-dependent kinase inhibitor 2A; p16/INK4A), MGMT,
MLH1, and others, are silenced by promoter methylation in
colorectal cancer [2]. A subset of colorectal cancer cases ex-
hibits promoter methylation inmultiple genes, referred to as CpG
island methylator phenotype (CIMP) [2–4]. CIMP+ colorectal
tumors appear to have a distinct clinical and molecular profile,
including associations with the female sex, proximal tumor
location, high frequencies of microsatellite instability (MSI), and
BRAF mutations [4–12]. Promoter CpG island methylation has
been shown to occur early in colorectal carcinogenesis [13–15].
Cyclooxygenase-2 (COX-2 or PTGS2, the HUGO-approved
gene symbol) has been considered to be important in colorectal
carcinogenesis [16] and has been shown to be expressed in
approximately 70% to 80% of colorectal cancer cases [17–19].
COX-2 overexpression is considered to be important in the
early stage of colorectal cancer development [20]. A study
showed that COX-2 overexpression was associated with poor
prognosis [18], whereas another study showed that COX-2
expression was not correlated with poor survival [17]. The
COX inhibitor aspirin has been known to decrease the risk for
colorectal cancer [21], and the new COX-2–specific inhibitor
celecoxib has been shown to inhibit the growth of colorectal
cancer cells in vitro [22,23]. Thus, COX-2 is an attractive
chemopreventive target [16,24,25]. COX-2 overexpression
has been shown to be inversely associated with MSI-high
(MSI-H) [26,27] and CIMP [28]. Aspirin has been shown to act
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through COX-independent mechanisms by increasing pro-
tein expression and subsequent apoptosis in mismatch re-
pair [29]. COX-2 expression has been shown to be regulated
by wild-type p53, suggesting that TP53 mutation may cause
deregulation of COX-2 expression [30]. p53 mutations have
also been shown to be inversely associated with MSI-H [31]
and CIMP [4]. Although both COX-2 and p53 are important
molecules in colorectal carcinogenesis and both CIMP and
MSI appear to be important molecular features, no study
to date has comprehensively examined interrelations be-
tween COX-2, p53, CIMP, and MSI in colorectal cancer.
One way of dissecting these interrelations is to correlate
the combined status of COX-2 and p53 expressions with
the combined CIMP and MSI status.
In this study, using a quantitative real-time polymerase
chain reaction (PCR; MethyLight) assay [11,32–35] and
relatively unbiased samples of colorectal cancer from two
large prospective cohort studies, we quantified DNA methyl-
ation in five CIMP-specific gene promoters and assessed
the interrelations between COX-2, p53, MSI, and CIMP in
colorectal cancer. In contrast to methylation-specific PCR
(MSP), which has widely been used in previous studies
[4–10,36], MethyLight can reliably distinguish high levels
from low levels of DNA methylation, with the latter likely
having little or no biologic significance [33,34,37].
Materials and Methods
Study Group
To recruit patients into this study, we used the databases
of two large prospective cohort studies: the Nurses’ Health
Study (n = 121,700 women), which has been in progress
since 1976 and is managed by the Channing Laboratory at
the Brigham and Women’s Hospital (Boston, MA) [38], and
the Health Professional Follow-up Study (n = 51,500 men),
which has been in progress since 1986 and is managed by
the Harvard School of Public Health (Boston, MA) [39].
Informed consent was obtained from all participants before
inclusion in the cohorts. All cohort participants were free of
cancer (except for nonmelanoma skin cancer) at the time of
study entry. A subset of the cohort participants developed
colorectal cancer during prospective follow-up. We excluded
cases if adequate paraffin-embedded tumor tissue was not
available for quantitative DNA methylation analysis at the
time of this study, or if there were not enough tissue sections
for the evaluation of COX-2 and p53 expression. As a result,
751 colorectal cancer cases (328 from the men’s cohort and
423 from the women’s cohort) were included in this study.
Tissue collection and analyses were approved by the In-
stitutional Review Boards of the Dana-Farber Cancer Insti-
tute and the Brigham and Women’s Hospital.
Genomic DNA Extraction
To enrich tumor DNA, areas composed entirely of tumor
were encircled with a pen on the coverslip of a hematoxylin
and eosin (H&E)–stained tumor slide. Using the marked
H&E slide as a guide, the tumor tissue was dissected man-
ually from additional tissue sections by a sterile needle.
Normal tissue was obtained from normal colorectal tissues
at the margins of resection specimens. Dissected tissue
was placed in buffered proteinase K solution at 56jC for
3 hours. Genomic DNA was extracted using QIAmp DNA
Mini Kit (Qiagen, Valencia, CA), according to the manufac-
turer’s instructions.
Quantitative Real-Time PCR for DNA Methylation
(MethyLight)
Sodium bisulfite treatment on genomic DNA was per-
formed as previously described [37]. Real-time PCR was
performed as previously described to measure DNA meth-
ylation (MethyLight) [32–34]. We used ABI 7300 (Applied
Biosystems, Foster City, CA) for quantitative real-time PCR.
Using five sets of primers and probes, we amplified five CIMP-
specific promoters [CACNA1G (calcium channel, voltage-
dependent, T type a-1G subunit), CDKN2A (p16/INK4A),
CRABP1 (cellular retinoic acid binding protein 1), MLH1,
and NEUROG1 (neurogenin 1)] [11]. COL2A1 (the collagen
2A1 gene) was used to normalize for the amount of input
bisulfite-converted DNA [11]. Primers and probes were pre-
viously described as follows:CACNA1G,CRABP1, andNEU-
ROG1 [11]; CDKN2A and COL2A1 [34]; and MLH1 [37]. The
percentage of methylated reference (PMR) at a specific locus
was calculated by dividing the GENE:COL2A1 ratio of a
sample by the GENE:COL2A1 ratio of SssI-treated human
genomic DNA (presumably fully methylated) and by multi-
plying this value by 100 [32,33]. A PMR cutoff value of 4
was based on previously validated data [11,32–34,37]. The
precision and performance characteristics of bisulfite con-
version and subsequent MethyLight assays have been pre-
viously evaluated, and assays have been validated [37].
CIMP-highwas defined as the presence ofz 4methylated
promoters among five gene promoters, includingCACNA1G,
CDKN2A, CRABP1, MLH1, and NEUROG1 [11]. CIMP-low
was defined as the presence of one to three of fivemethylated
promoters. CIMP-0 was defined as the absence of methyla-
tion in any of the five promoters. We have demonstrated that
CIMP-low tumors appear to have features different from
those of CIMP-high and CIMP-0 tumors (submitted for pub-
lication). We have previously validated the use of these five
markers in our CIMP-specific panel, and all of the five
markers showed high sensitivity (> 90%) and/or specificity
(> 90%) for the prediction of CIMP status [11].
MSI Analysis
For microsatellite analyses, whole genome amplification
of genomic DNA was performed by PCR using random 15-
mer primers, as previously described [40]. Methods for MSI
analysis were as previously described [19]. Briefly, the status
of MSI was determined by analyzing the variability in the
length ofmicrosatellitemarkers from tumor DNA compared to
that from normal DNA. In addition to the recommended MSI
panel consisting of D2S123, D5S346, D17S250, BAT25, and
BAT26, we used BAT40, D18S55, D18S56, D18S67, and
D18S487 (i.e., a 10-marker panel). PCR and DNA fragment
analysis for all of the markers, except for D2S123, D5S346,
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and D17S250, was performed in duplicate. A high degree of
MSI (MSI-H)was defined as having instability in 30% or more
of the markers. MSI-low (MSI-L) was defined as having
instability in less than 30% of the markers, andmicrosatellite
stability (MSS) was defined as having no unstable marker.
We combined MSI-L and MSS tumors into one group desig-
nated as ‘‘MSI-L/MSS.’’
Tissue Microarray (TMA) Construction
TMAs were constructed at the Dana-Farber/Harvard Can-
cer Center TMA Core Facility, as previously described
[41,42], with some modifications. H&E–stained slides were
reviewed by a pathologist (S.O.) to mark highly cellular por-
tions to guide donor tissue core selection. TMAs were con-
structed using Automated Arrayer (Beecher Instruments,
Sun Prairie, WI). Two 0.6-mm tissue cores each from tumor
and normal colonic mucosa were placed in each TMA block.
Each TMA block will have a total of approximately 400 cores
(100 cases). A previous validation study demonstrated that
the analysis of two disks was comparable to the analysis of
the whole tissue section in more than 95% of cases and that
proteins retained their antigenicity for > 60 years [43]. We
analyzed whole tissue sections for cases in which there was
not enough tumor tissue for TMAs, or for cases in which
results were equivocal or indeterminate in TMAs.
Immunohistochemistry for COX-2 and p53
The methods for COX-2 and p53 immunohistochemistry
were as previously described [19]. Using normal colonic
mucosa as a reference, COX-2 expression was interpreted
as negative (no overexpression compared to normal mu-
cosa), weakly positive (1+), or strongly positive (2+) (Fig-
ure 1). Inflammatory cells served as internal positive control.
Only strong and unequivocal nuclear staining for p53 in 50%
or more of tumor cells was interpreted as p53+. Appropriate
positive and negative controls were included in each run of
COX-2 and p53 immunohistochemistry. All immunohisto-
chemically stained slides were interpreted by a pathologist
(S.O.) who was blinded from any other laboratory data.
Statistical Analysis
In statistical analysis, chi-square analysis (or Fisher’s exact
test when any category was less than 10) was performed
for categorical data, using the SAS program (version 9.1;
SAS Institute, Cary, NC). All P values were two-sided, and
statistical significance was set at P = .05.
Results
p53 and COX-2 Expressions and CIMP
We obtained 751 colorectal cancer specimens and quan-
tified DNA methylation in a panel of the five CIMP-specific
promoters (CACNA1G, CDKN2A, CRABP1, MLH1, and
NEUROG1) [11] by MethyLight technology. Among the
751 colorectal cancer cases, 115 (15%) tumors were classi-
fied as CIMP-high (z 4 of 5 methylated promoters), 251
(33%) were classified as CIMP-low (1 to 3 of 5 methylated
promoters), and the remaining 385 (51%) were classified as
CIMP-0 (no methylated promoters). We also evaluated p53
expression by immunohistochemistry in the 751 colorectal
cancer cases, with 321 (43%) showing positive staining.
Figure 1. COX-2 immunohistochemistry in colorectal cancer. (A) No COX-2 overexpression (negative) in carcinoma (bottom, solid arrows) relative to normal
mucosa (top, empty arrow). (B) Weak (1+) overexpression in carcinoma (bottom, solid arrows) relative to normal mucosa (top, empty arrow). (C) Strong (2+)
overexpression in carcinoma (top right, solid arrows; normal mucosa at bottom left, empty arrow). (D) Strong (2+) overexpression in carcinoma (top right, solid
arrows; normal mucosa at bottom left, empty arrow).
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CIMP-high was significantly more common in p53 tumors
(22%) than in p53+ tumors (6.5%; P < .0001) (Table 1).
Among 611 tumors in which COX-2 expression in tumors
relative to normal mucosa could be evaluated, 398 (65%)
tumors strongly (2+) overexpressed COX-2, 114 (19%) tu-
mors weakly (1+) overexpressed COX-2, and 99 (16%) tu-
mors were negative for COX-2 overexpression. CIMP-high
was significantly more common in COX-2 tumors (23%)
than in COX-2 strongly positive (2+) tumors (12%; P = .003)
(Table 1) and COX-2+ (1+ or 2+) tumors (13%; P = .009).
Combined p53/COX-2 Status, CIMP, and MSI
Because of an important role of p53 in regulating COX-2
expression, we correlated the combined status of p53 and
COX-2 expressions with CIMP in colorectal cancer cases
(Table 2). Among 544 tumors for which we had data on
COX-2, p53, and CIMP, there was a significant positive cor-
relation between COX-2 and p53 expressions (P = .0003).
CIMP-high was significantly less common in COX-2+/p53+
tumors (4.6%) than in COX-2+/p53 tumors (19%;P < .0001),
COX-2/p53+ tumors (17%; P = .04), and COX-2/p53
tumors (28%; P < .0001), indicating a synergistic effect of
p53 and COX-2 positivity on decreasing CIMP-high fre-
quency. There was a trend toward higher frequencies of
CIMP-high among women’s tumors than among men’s tu-
mors in each COX-2/p53 subgroup of tumors, although sta-
tistical significance was not reached in any of the COX-2/p53
subgroups (Table 2).
We also correlated the combined status of p53 and
COX-2 with the MSI status of colorectal cancer cases.
MSI-H was less common in COX-2+/p53+ tumors [11 of
209 (5.3%)] than in COX-2+/p53 tumors [42 of 233 (18%);
P < .0001], COX-2/p53+ tumors [3 of 23 (13%); P = .15], and
COX-2/p53 tumors [20 of 61 (33%); P < .0001], indicating
a synergistic effect of p53 and COX-2 positivity on decreas-
ing MSI-H frequency.
Six MSI/CIMP Subtypes of Colorectal Cancer
and the Combined Status of COX-2/p53
To analyze the effects of CIMP and MSI status on COX-2/
p53, we subclassified colorectal cancer cases into six cate-
gories on the basis of CIMP and MSI status [i.e., MSI-H
CIMP-high (n = 52), MSI-H CIMP-low (n = 9), MSI-H CIMP-0
(n = 15), MSI-L/MSS CIMP-high (n = 25), MSI-L/MSS CIMP-
low (n = 163), and MSI-L/MSS CIMP-0 (n = 262)]. We as-
sessed COX-2 and p53 expressions in each category. The
frequencies of COX-2+/p53+ tumors were significantly less
common in MSI-H CIMP-high tumors (9.6%) than in MSI-H
CIMP-0 tumors (33%;P = .04), MSI-L/MSSCIMP-low tumors
(47%; P < .0001), and MSI-L/MSS CIMP-0 tumors (44%;
P < .0001) (Figure 2). The frequencies of COX-2+/p53+
tumors were also less common in MSI-H CIMP-low tumors
(11%) than inMSI-L/MSSCIMP-low tumors (47%;P = .04). In
contrast, the frequencies of COX-2/p53 tumors were
significantly more common in MSI-H CIMP-high tumors
(27%) than in MSI-L/MSS CIMP-low (14%; P = .02) and
in MSI-L/MSS CIMP-0 tumors (6.1%; P < .0001) (Figure 3).
The frequencies of COX-2/p53 tumors were also more
Table 1. Frequencies of CIMP-0, CIMP-Low, and CIMP-High in Colorectal Cancer Cases with Various COX-2 and p53 Statuses.
Number of Methylated Promoters CIMP-Low CIMP-High
0 (CIMP-0)
[n (%)]
1 (n) 2 (n) 3 (n) 4 (n) 5 (n)
(1–3) [n (%)] (z 4) [n (%)]
All cases (n = 751) 385 (51) 131 77 43 45 70 251 (33) 115 (15)
p53+ tumors (n = 321) 179 (56) 76 29 16 9 12 121 (38) 21 (6.5)*
p53 tumors (n = 430) 206 (48) 55 48 27 36 58 130 (30) 94 (22)*
COX-2 strongly positive (2+) tumors (n = 398) 228 (57) 72 36 15 21 26 123 (31) 47 (12)y
COX-2 weakly positive (1+) tumors (n = 114) 59 (52) 18 12 5 13 7 35 (31) 20 (17)
COX-2 tumors (n = 99) 35 (35) 17 16 8 5 18 41 (41) 23 (23)y
*p53+ vs p53 (P < .0001).
yNegative COX-2 vs strongly positive (2+) COX-2 (P = .003).
Table 2. Frequencies of CIMP-High in Colorectal Cancer Cases with Various
Combined COX-2/p53 Statuses.
Tumors Frequency of CIMP-High
Men and Women Men Women
COX-2+/p53+ 4.6% (10/218)*yz 3.1% (3/96) 5.7% (7/122)
COX-2+/p53 19% (46/237)* 14% (14/103) 23% (32/137)
COX-2/p53+ 17% (4/24)y 10% (1/10) 21% (3/14)
COX-2/p53 28% (18/65)z 17% (5/30) 37% (13/35)
*COX-2+/p53+ vs COX-2+/p53 (P < .0001).
yCOX-2+/p53+ vs COX-2/p53+ (P = .04).
zCOX-2+/p53+ vs COX-2/p53 (P < .0001).
Figure 2. Frequencies of COX-2+/p53+ tumors in the six MSI/CIMP subtypes
of colorectal cancer.
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common in MSI-H CIMP-low tumors (33%) than in MSI-L/
MSS CIMP-0 tumors (6.1%; P = .02). Therefore, MSI-H and
CIMP-high were synergistically inversely associated with
positivity for both COX-2 and p53.
Discussion
We conducted this study to evaluate the interactions of
COX-2 and p53 expressions and their relations with CIMP
and MSI in colorectal cancer. We demonstrated that there
were inverse correlations of each of the COX-2 and p53 over-
expressions with CIMP-high, and that COX-2 and p53 over-
expressions were synergistically inversely associated with
both CIMP-high and MSI-H. Our data imply that CIMP-low/
CIMP-0 tumors tend to activate the COX-2 pathway in part
throughmutations of p53, a COX-2 regulator, whereas CIMP-
high tumors tend not to mutate the p53 gene or to over-
express COX-2. Our data also suggest that, compared to the
use of COX-2 or p53 analysis alone, the use of combined
immunohistochemical analysis for both COX-2 and p53 may
better serve for the molecular classification of colorectal
cancer. The apparent synergistic effect of COX-2 and p53
might also reflect the limitations of immunohistochemical
assays in which false positives and false negatives can occur,
and the combined analysis for COX-2 and p53 might select
tumors that are caused by COX-2 activation, which can, in
turn, be caused by mutations and functional loss of p53.
It has been shown that the correlation of TP53 gene muta-
tions and p53 positivity by immunohistochemistry is less
than perfect [44]. Thus, the combination of COX-2 and p53
immunohistochemistry might be useful to decrease false
positives and false negatives, or to select a more homoge-
nous group of colorectal cancer cases.
We used quantitative real-time PCR (MethyLight) to dis-
tinguish high levels from low levels of DNA methylation.
Assays to measure DNA methylation may be potentially very
useful in clinical practice because many tumor-suppressor
genes have been shown to be methylated and functionally
silenced in a variety of human neoplasias [1] DNA methyla-
tion may be a useful marker for predicting prognosis, for
monitoring the efficacy of adjuvant therapy in cancer patients
[45], and for performing risk assessment in the surveillance of
high-risk or low-risk individuals [46,47]. Previous studies on
CIMP in colorectal cancer [3,6–8,12] have primarily used
methylation-specific PCR (MSP). MSP is a qualitative assay
and cannot reliably distinguish high levels from very low
levels of methylation. Using quantitative MethyLight as-
says, we have shown that low levels of promoter methyla-
tion do not typically silence gene expression, suggesting that
low levels of DNA methylation have no or little biologic sig-
nificance [37]. Studies using MSP may overestimate the fre-
quency of methylation positivity in a given methylation
marker, hence the frequency of CIMP. In our study, the use
of quantitative DNA methylation assays and relatively unbi-
ased samples of colorectal cancer from two large prospective
cohorts has enabled us to precisely estimate the frequency
of colorectal cancer cases with a specific molecular feature
(i.e., CIMP, MSI-H, or Cox-2+) at a population level.
The mechanisms of COX-2 regulation are still largely
unknown. COX-2 expression has previously been shown to
be repressed by wild-type p53 [30], although p53 is unlikely
the only regulator of COX-2. Thus, tumors with wild-type p53
may have a lower frequency of COX-2 overexpression.
Indeed, our data support this hypothesis. The frequency of
COX-2 tumors was higher among p53 tumors than among
p53+ tumors, and COX-2 and p53 statuses were positively
correlated with each other. For therapeutic approaches tar-
geting the COX-2 pathway, it may be important to consider
the effects of wild-type or mutant p53, potentially modulat-
ing signaling through the COX-2 pathway. Further study is
necessary to investigate the mechanisms of COX-2 regula-
tion by p53.
Our data may have significant clinical implications be-
cause of the emerging importance of both COX-2 and DNA
methylation as promising chemotherapeutic/chemopre-
ventive targets. Previous studies demonstrated that MSI-H
tumors, whether in sporadic or familial setting, are inversely
associated with COX-2 overexpression [26,27]. In addition,
our data suggest a synergistic effect of CIMP and MSI-H on
lowering the frequency of COX-2 and p53 overexpression
in colorectal cancer. Elucidating the molecular mechanisms
of COX-2 overexpression and its action in COX-2–over-
expressed tumors and the alternative mechanisms that may
bypass COX-2 overfunction in COX-2 tumors is important
for the purpose of developing molecularly targeted treat-
ments against colorectal cancer.
The prognostic significance of CIMP stratified byCOX-2 or
p53 status has not been studied. Hawkins et al. [6] showed
that patients with MSS/CIMP tumors experienced worse
survival compared to patients with either MSS/non-CIMP
tumors or MSI-H tumors. However, their data may have been
confounded by the fact that, in their study, CIMP tumors were
associated with advance stage at initial presentation [6]. In
contrast, Van Rijnsoever et al. [5] demonstrated that CIMP
positivity conferred improved survival among patients who
received 5-fluorouracil–based adjuvant chemotherapy for
stage III colorectal cancer cases. We have previously exam-
ined promoter methylation in 25 of 34 advanced colorectal
Figure 3. Frequencies of COX-2/p53 tumors in the six MSI/CIMP subtypes
of colorectal cancer.
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cancer cases in phase I/II clinical trials of combination chemo-
therapy with gefitinib (an epidermal growth factor receptor
tyrosine kinase inhibitor) [48], but we found no CIMP-high
tumors (unpublished data).We found that combined positivity
for both p21 and p53, but not COX-2 status, was a significant
predictor of tumor resistance to combination chemotherapy
with gefitinib [48]. Further studies are necessary to determine
whether CIMP stratified by COX-2 or p53 status is signifi-
cantly associated with improved or worse patient outcomes.
Our prospective cohort studies, the Nurses’ Health Study
(n = 120,000; followed since 1976) [38] and the Health Pro-
fessional Follow-up Study (n = 51,000; followed since 1986)
[39], are currently ongoing. Thus, relational data on patient
survival and CIMP will be available in the future.
In conclusion, COX-2 and p53 overexpression exhibits
synergistic inverse correlations with CIMP-high and MSI-H.
Our data suggest that a combined analysis of COX-2 and p53
may be more useful for the molecular classification of colo-
rectal cancer than either COX-2 or p53 analysis alone.
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